Verastem, Inc. (VSTM)

NASDAQ: VSTM · IEX Real-Time Price · USD
3.100
-0.060 (-1.90%)
At close: Jun 24, 2024, 4:00 PM
3.169
+0.069 (2.23%)
After-hours: Jun 24, 2024, 7:32 PM EDT
-1.90%
Market Cap 78.51M
Revenue (ttm) n/a
Net Income (ttm) -105.52M
Shares Out 25.33M
EPS (ttm) -4.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 351,793
Open 3.150
Previous Close 3.160
Day's Range 3.040 - 3.190
52-Week Range 3.045 - 14.220
Beta 0.27
Analysts Strong Buy
Price Target 25.69 (+728.71%)
Earnings Date Aug 6, 2024

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 27, 2012
Employees 73
Stock Exchange NASDAQ
Ticker Symbol VSTM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price forecast is $25.69, which is an increase of 728.71% from the latest price.

Price Target
$25.69
(728.71% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM

NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ: VSTM). Such investors are advised to cont...

1 hour ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM

NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM). Such investors are advised to c...

2 days ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM).   Such investors are advised t...

11 days ago - GlobeNewsWire

VERASTEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Verastem, Inc. on Behalf of Verastem Stockholders and Encourages Investors to Contact the Firm

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Verastem, Inc. (“Verastem” or th...

14 days ago - GlobeNewsWire

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM)

NEW YORK--(BUSINESS WIRE)---- $VSTM #Investor--The law firm of Kirby McInerney LLP is investigating potential claims against Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM). The investigat...

17 days ago - Business Wire

Verastem opened 70% down on Friday: what happened?

Verastem Inc (NASDAQ: VSTM) opened nearly 70% down this morning even though the pharmaceutical firm reported positive interim data for its combination therapy as a treatment of pancreatic cancer.  Her...

4 weeks ago - Invezz

Harvest ETFs announces May 2024 Distributions

OAKVILLE, Ontario--(BUSINESS WIRE)--Harvest Portfolios Group Inc. (“Harvest”) announces the following distributions for Harvest ETFs for the month ending May 31, 2024. The distribution will be paid on...

Other symbols: CLF
4 weeks ago - Business Wire

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has initiated the rolling ...

4 weeks ago - Business Wire

Verastem shares surge more than 50% after pancreatic-cancer treatment study data

Shares of Verastem VSTM, +2.53% rose late Thursday after interim data from the company's trial evaluating a combination therapies to treat pancreatic cancer showed a high overall response rate.

4 weeks ago - Market Watch

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and eff...

4 weeks ago - Business Wire

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported fina...

6 weeks ago - Business Wire

Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will part...

6 weeks ago - Business Wire

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M...

2 months ago - Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purc...

2 months ago - Business Wire

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced new results from the first-ever gl...

3 months ago - Business Wire

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three mon...

3 months ago - Business Wire

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced multiple oral and poster presentat...

3 months ago - Business Wire

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and Drug Administration (FD...

3 months ago - Business Wire

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients, today announced that preclinical data will be presented in fiv...

3 months ago - Business Wire

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities and up...

5 months ago - Business Wire

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the U.S. Food and Drug Administrati...

5 months ago - Business Wire

Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company wi...

5 months ago - Business Wire

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-i...

6 months ago - Business Wire

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initia...

6 months ago - Business Wire

New Healthcare Professional Component of Let's Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the launch of the new healthcare ...

8 months ago - Business Wire